Last reviewed · How we verify
megestrol
At a glance
| Generic name | megestrol |
|---|---|
| Also known as | Megestrol acetate, megestrol acetate |
| Sponsor | National Center for Research Resources (NCRR) |
| Target | Cytochrome P450 2C9, Multidrug resistance protein 1, Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Anorexia from HIV
- Cachexia due to HIV
- Endometrial carcinoma
- Hormone receptor positive malignant neoplasm of breast
- Nutritional deficiency associated with AIDS
Common side effects
- Diarrhea
- Impotence
- Rash
- Flatulence
- Hypertension
- Asthenia
- Insomnia
- Nausea
- Anemia
- Fever
- Libido Decreased
- Dyspepsia
Serious adverse events
- Pulmonary Embolism
- Thrombophlebitis
- Thromboembolic Phenomena
- Glucose Intolerance
- Cardiomyopathy
- Sarcoma
- Convulsion
- Leukopenia
Key clinical trials
- Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers (PHASE1, PHASE2)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer (PHASE3)
- Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer (PHASE2)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (PHASE3)
- Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- megestrol CI brief — competitive landscape report
- megestrol updates RSS · CI watch RSS
- National Center for Research Resources (NCRR) portfolio CI